EKF Diagnostics Holdings plc (EKDHF)

Market Cap	135.21M +18.9%
Revenue (ttm)	69.40M +2.7%
Net Income	2.86M -66.0%
EPS	0.01 -65.8%
Shares Out	n/a
PE Ratio	47.34
Forward PE	14.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Average Volume	20,658
Open	0.3398
Previous Close	0.3516
Day's Range	0.3398 - 0.3398
52-Week Range	0.2383 - 0.4237
Beta	0.53
RSI	44.00
Earnings Date	Mar 24, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 297
• Stock Exchange: OTCMKTS
• Ticker Symbol: EKDHF

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.

Financial numbers in GBP